Abstract:Key PointsMuscle wasting is a debilitating condition that develops with ageing and more rapidly with inactivity (bed rest) and in various systemic diseases (for example, cancer, renal failure, chronic obstructive pulmonary disease, sepsis, HIV and trauma). Fibre atrophy primarily results from an acceleration of protein degradation, often combined with reduced protein synthesis. Treatments that prevent this activation of proteolysis or increase protein synthesis offer considerable promise to combat this debilitating process.Various types of rapid muscle wasting develop through a common transcriptional programme involving the induction of a set of atrophy-related genes (atrogenes) by forkhead box protein O (FOXO) transcription factors and reduced signalling by the PI3K–AKT–mTOR pathway.The resulting muscle weakness is a consequence of the degradation of myofibrils, which is catalysed by ubiquitin ligases that target different components of the contractile apparatus for proteasomal degradation. By contrast, the loss of endurance results from the breakdown of mitochondria via autophagy.Myostatin, an autocrine inhibitor of normal muscle growth, and its circulating homologue activin A, also trigger muscle protein loss in various catabolic states via the activation of SMAD2 and SMAD3, which function together with FOXO transcription factors.Antibodies against myostatin or activin A, or agents that block their receptor — activin A receptor, type IIB (ActRIIB) — in muscle could be a promising approach to combat muscle loss caused by cancer-associated cachexia, renal failure and ageing. Indeed, these treatments helped to preserve muscle and prolong longevity in tumour-bearing mice, and several of these treatments are currently in clinical trials.Glucocorticoids and various circulating inflammatory mediators, such as tumour necrosis factor-α (TNFα) and interleukin-6 (IL-6), have also been implicated in excessive muscle proteolysis in cachexia, but their roles in different catabolic states remain uncertain and controversial.Recent studies have increased our understanding of the biochemical mechanisms of atrophy and have identified many intracellular proteins that are crucial in muscle wasting (for example, SMADs, tripartate motif-containing protein 32 (TRIM32), nuclear factor-κB (NF-κB)) or that combat this process (for example, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α), sirtuin1 (SIRT1) and JUNB). Their manipulation by small molecules offers many opportunities for the rational design of new treatments for this condition.

The Molecular Mechanisms and Prevention Principles of Muscle Atrophy in Aging.

Targeting Mitochondrial Quality Control in Muscle Aging: Natural Dietary Products As Potential Interventions

Skeletal muscle atrophy: From mechanisms to treatments

Cellular and molecular mechanisms of muscle atrophy

Mechanisms of muscle atrophy and hypertrophy: implications in health and disease

Post‐translational regulation of muscle growth, muscle aging and sarcopenia

Mechanisms of muscle cells alterations and regeneration decline during aging

Muscle wasting in disease: molecular mechanisms and promising therapies

Micro(RNA)-managing muscle wasting

Nutritional Strategies for Muscle Atrophy: Current Evidence and Underlying Mechanisms

Skeletal muscle oxidative stress and inflammation in aging: Focus on antioxidant and anti-inflammatory therapy

Oxidative stress: roles in skeletal muscle atrophy

Aging and Autophagy: Roles in Musculoskeletal System Injury

Ubiquitin-proteasome pathway in skeletal muscle atrophy

Factors, mechanisms and improvement methods of muscle strength loss

The Effect of Metabolites on Mitochondrial Functions in the Pathogenesis of Skeletal Muscle Aging

Life-Long Aerobic Exercise is a Non-Pharmacological Approach for Inducing Autophagy and Delaying Muscle Atrophy in the Aging Population

An Integrated Approach to Skeletal Muscle Health in Aging

Reduced energy metabolism contributing to aging of skeletal muscle by serum metabolomics and gut microbiota analysis

Epigenetics of Skeletal Muscle Atrophy

Mitochondrial Dynamics and Mitophagy in Skeletal Muscle Health and Aging